Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Neulasta Biosimilar From Coherus Needs Better Immunogenicity Assay After Stumble At US FDA

Jun 12 2017

• By Sue Sutter

FDA entrance sign 2016

Related Content

Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts

Apr 22 2017

Can Biosimilar Studies Be Conducted Solely In Healthy Volunteers?

May 16 2017

Apotex Moves To Block Coherus' Neulasta Biosimilar; Asks FDA To Require Patient Studies

May 01 2017

Pending Biosimilars

Feb 13 2017

Mylan's Next Up For A Shot At Neulasta Biosimilar After Coherus CRL

Jun 12 2017

FDA Met Biosimilar Review Timelines But Missed Meeting Goals In 2015

Apr 25 2016

Biosimilars: Sandoz Pegfilgrastim Review, Amgen Adalimumab Launch Extended To 2018

Oct 29 2016

Related Companies

Coherus Oncology, Inc.

Amgen, Inc.

Apotex Inc.

Samsung Bioepis Co., Ltd.

Merck & Co., Inc.

Johnson & Johnson

Novartis AG

Novartis AG

Viatris Inc.

Biocon, Ltd.

Additional Topics

United States Biosimilars Complete Response Letters Regulation BioPharmaceutical Cancer

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window